These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34253805)

  • 21. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
    BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.
    Ottaiano A; Santorsola M; Ianniello M; Ceccarelli A; Casillo M; Sabbatino F; Petrillo N; Cascella M; Caraglia F; Picone C; Perri F; Sirica R; Zappavigna S; Nasti G; Savarese G; Caraglia M
    J Transl Med; 2024 Apr; 22(1):379. PubMed ID: 38650006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
    Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
    Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
    Lin YL; Liu KL; Lin BR
    Medicine (Baltimore); 2020 Oct; 99(43):e22780. PubMed ID: 33120790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
    Takahashi M; Sakamoto Y; Ohori H; Tsuji Y; Kuroki M; Kato S; Otsuka K; Komine K; Takahashi M; Takahashi S; Shirota H; Ouchi K; Takahashi Y; Imai H; Shibata H; Yoshioka T; Tanaka M; Yamaguchi H; Yamaguchi T; Shimodaira H; Ishioka C
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):393-402. PubMed ID: 34028598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
    Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    Xu J; Kim TW; Shen L; Sriuranpong V; Pan H; Xu R; Guo W; Han SW; Liu T; Park YS; Shi C; Bai Y; Bi F; Ahn JB; Qin S; Li Q; Wu C; Ma D; Lin D; Li J
    J Clin Oncol; 2018 Feb; 36(4):350-358. PubMed ID: 29215955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
    Mulet N; Matos I; Noguerido A; Martini G; Élez ME; Argilés G; Tabernero J
    Expert Opin Pharmacother; 2018 Apr; 19(6):623-629. PubMed ID: 29537896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
    Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
    J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
    Jalali A; Gard G; Banks S; Dunn C; Wong HL; Wong R; Lee M; Gately L; Loft M; Shapiro JD; Kosmider S; Tie J; Ananda S; Yeung JM; Jennens R; Lee B; McKendrick J; Lim L; Khattak A; Gibbs P
    Curr Probl Cancer; 2022 Apr; 46(2):100793. PubMed ID: 34565601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
    Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G
    Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial.
    Pietrantonio F; Fucà G; Manca P; Pagani F; Raimondi A; Prisciandaro M; Randon G; Corti F; de Braud F; Cremolini C; Miceli R
    Tumori; 2021 Aug; 107(4):353-359. PubMed ID: 33021466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
    Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
    Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
    Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
    ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
    Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
    BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.